IBRXImmunityBio, Inc.

Filed with the SEC on November 9, 2026 | Form 10-Q | Q3 FY2026

Metric	Q3 FY2026
Revenue	$75.0M
Operating Loss	$(191.3M)
Net Loss	$(289.5M)
EPS (Basic & Diluted)	$(0.32)
Stock Price (at time of report)	$6.69
Today's Change	-22.52%

---

What Happened

ImmunityBio, Inc. filed its quarterly report on Form 10-Q with the SEC on November 9, 2026, covering the third fiscal quarter of FY2026. The company reported revenues of $75.0 million for the quarter, while simultaneously recording an operating loss of $191.3 million and a net loss of $289.5 million, translating to a basic and diluted loss per share of $0.32. The magnitude of the net loss — running at nearly four times reported revenues — has sent shares sharply lower, with IBRX trading down 22.52% on the day to $6.69.

Why It Matters

For investors, the core tension in this filing is straightforward: revenue is real and measurable at $75 million, but the company is burning cash at a pace that significantly exceeds its top line. The gap between operating loss ($191.3M) and net loss ($289.5M) — a difference of roughly $98 million — suggests that below-the-line charges, potentially including interest expense, non-cash items, or other financing costs, are adding a substantial additional burden on top of already-heavy operating losses. Until the path to narrowing this gap becomes clearer, the quarterly cash burn rate will remain the dominant concern for the near-term investment thesis. The stock's sharp single-day decline indicates the market found this quarter's loss profile meaningfully worse than anticipated.

Analysis

The $75 million revenue figure is not trivial — it represents a commercially active business rather than a pre-revenue clinical-stage company. However, the structure of the losses demands scrutiny. An operating loss of $191.3 million on $75 million in revenue implies an operating margin of approximately -255%, which signals that the company's cost base — likely a combination of research and development expenditure, commercialization infrastructure, and general overhead — is running at multiples of what the revenue engine can currently support.

The incremental jump from operating loss to net loss (from $191.3M to $289.5M) is worth watching closely in the full filing detail; this roughly $98 million differential could reflect debt service costs on what has historically been a heavily leveraged balance sheet for IBRX, or it could include non-cash impairments or fair-value adjustments. That detail is not broken out in the structured XBRL data provided and would require a full review of the income statement footnotes.

Key things to watch going forward:

• Whether revenue trajectory is accelerating quarter-over-quarter, as growing commercial revenue is ultimately the only organic path to narrowing these losses
• The composition and trend of operating expenses — specifically R&D vs. SG&A — to assess whether spending is being directed toward future value creation or sustaining the current cost base
• Balance sheet liquidity and cash runway, given the scale of quarterly cash consumption implied by this loss level
• Any guidance or commentary from management on the pace of loss reduction or expected inflection points

StockWatch's initiating coverage on IBRX, published September 11, 2026, is worth revisiting in light of this quarter's results to assess how the revenue and loss trajectory compare to the assumptions embedded in that prior analysis.

Disclaimer

This report is a news and informational summary based solely on data extracted from ImmunityBio's SEC filing dated November 9, 2026. It does not constitute investment advice, a solicitation to buy or sell securities, or an equity research recommendation. No rating or price target is issued or implied herein. Investors should conduct their own due diligence and consult a qualified financial adviser before making investment decisions.

Existing Coverage

StockWatch has full coverage on IBRX, published 2026-09-11. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-09. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000099/ibrx-20260930.htm